Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease.

Shen, Joan Hq; Shen, Qi; Yu, Holly; Lai, Jin-Shei; Beaumont, Jennifer L; Zhang, Zhenxin; Wang, Huali; Kim, Seong Yoon; Chen, Christopher; Kwok, Timothy; Wang, Shuu-Jiun; Lee, Dong Young; Harrison, John; Cummings, Jeffrey
American journal of neurodegenerative disease
2014NA ; 3 ( 3 ) :158-69.
ÀúÀÚ »ó¼¼Á¤º¸
Shen, Joan Hq -
Shen, Qi -
Yu, Holly -
Lai, Jin-Shei -
Beaumont, Jennifer L -
Zhang, Zhenxin -
Wang, Huali -
Kim, Seong Yoon -
Chen, Christopher -
Kwok, Timothy -
Wang, Shuu-Jiun -
Lee, Dong Young -
Harrison, John -
Cummings, Jeffrey -
ABSTRACT
There is a lack of validated tools for assessing Alzheimer's disease (AD) across Asia. This study evaluates the psychometric properties of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Disability Assessment for Dementia (DAD), and Neuropsychological Test Battery (NTB) in Asian participants. Participants with mild to moderate AD (n=251) and healthy controls (n=51) from Mainland China, Taiwan, Singapore, Hong Kong, and South Korea completed selected instruments at several time points. Test-retest reliability was better than 0.70 for all tests. AD participants performed significantly more poorly than controls on every score. Within the AD group, greater disease severity corresponded to significantly poorer performance. The AD group test performance worsened over time and there was a trend for worse performance in AD compared to healthy controls over time. The ADAS-Cog, DAD, and NTB are reliable, valid, and responsive measures in this population and could be used for clinical trials across Asian countries/regions.
keyword
Alzheimer's disease; validation
¸µÅ©

ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
The AD group test performance worsened over time and there was a trend for worse performance in AD compared to healthy controls over time.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
PMID: 25628967
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå